[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Reblin
T
T
GlaxoSmithKline GmbH & Co. KG, Theresienhöhe 11, D-80339 München. Tjark.Reblin@gsk.com
Seidel
D
D
Stein
D
D
Görtz
A
A
Lander
T
T
D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control*; D015309:Glucose Clamp Technique; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D009203:Myocardial Infarction / Q000097:blood / Q000517:prevention & control*; D000077154:Rosiglitazone; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077154:Rosiglitazone; D013844:Thiazoles; D045162:Thiazolidinediones